Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
SNDX
SNDX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SNDX News
Syndax Partners with WODA to Expand Access to Revuforj in Multiple Regions
Jan 07 2026
Globenewswire
Syndax Pharmaceuticals Inc. Offers 10.4% Annualized Return on $13 Put Options
Dec 29 2025
NASDAQ.COM
Syndax's Revuforj® Wins Best New Drug at 2025 Scrip Awards
Dec 12 2025
Globenewswire
Syndax's Revuforj® Wins Best New Drug at 2025 Scrip Awards
Dec 12 2025
Newsfilter
JPMorgan Lowers Price Target for Syndax Pharmaceuticals (SNDX) to $33, Keeps "Overweight" Rating Intact
Nov 17 2025
Yahoo Finance
UBS Reiterates Buy Rating for Syndax Pharmaceuticals and Increases Price Target to $38
Nov 04 2025
Benzinga
Syndax aims for $10B market following Revuforj's NPM1 approval and a 21% increase in Q3 revenue.
Nov 03 2025
SeekingAlpha
Syndax to Hold In-Person and Webcast ASH Investor Event on December 8, 2025
Nov 03 2025
Newsfilter
Syndax Reveals Promising Data for Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Accepted for ASH 2025 Presentation
Nov 03 2025
Newsfilter
Syndax Pharmaceuticals Q3 2025 Earnings Forecast
Nov 02 2025
SeekingAlpha
Syndax to Take Part in Investor Conferences This November
Oct 30 2025
Newsfilter
BTIG Affirms Buy Rating for Syndax Pharmaceuticals, Keeps $56 Price Target Intact
Oct 27 2025
Benzinga
What’s Causing the Decline in Syndax Stock Today?
Oct 24 2025
Benzinga
Syndax Secures New Approval for Revuforj in Treating Acute Myeloid Leukemia
Oct 24 2025
SeekingAlpha
HC Wainwright & Co. Initiates Coverage on Syndax Pharmaceuticals with a Buy Rating and Sets Price Target at $40
Oct 16 2025
Benzinga
Biotech Stocks Awaiting FDA Verdict in October 2025
Sep 28 2025
NASDAQ.COM
Show More News
